SIMULATION 2: THE TALLY
Scene: Kavli Institute for Quantum Medicine, Chicago, Ana’s Office, March 2025
Setting
The Eckhardt Research Center—glass and steel, LEED Platinum, overlooking the Midway Plaisance. Ana’s office is on the 4th floor. It’s messy in a specific way: stacks of paper printouts (she thinks better on paper), a wooden tally stick on her desk (her father’s, carved with inventory marks), a photo of Sarah and their niece Mei.
On her whiteboard: an equation. Over and over, variations of the same form.
I = -ln(P)/S
Where:
I = Inversion index (measure of system creativity/survival)
P = Probability of observed state
S = System complexity
She’s been trying to falsify it for six months. It won’t die.
ANA
She’s 35, wearing a blazer over a band t-shirt (Sleater-Kinney, vintage). She runs on coffee and righteous anger. Her father called from the store this morning—the one he still runs, barely, on the South Side. Landlord raised rent. Again.
The Institute wants her to present to the Board next week. The corporate partners: UnitedHealth, Pfizer, Anthem. They want to see “deliverables.”
But her model keeps showing the wrong thing.
She’s been running healthcare outcome data through her information-theory framework. The hypothesis: More efficient healthcare (less waste, optimized resource allocation) should correlate with better population health.
The data shows the opposite.
Not just no correlation. Negative correlation.
Systems with maximum efficiency—Singapore’s centralized health database, certain HMO models—show declining innovation in treatment. New drug adoption slows. Patient outcomes plateau, then decline. The systems become brittle.
Systems with “waste”—redundant research, competing approaches, unoptimized resource distribution—show breakthroughs. The “wasted” effort creates optionality. The stochasticity saves lives.
She pulls up the graph. The “Inverter Curve”:
System Health
│
│ ╭──────╮
│ ╱ ╲_____
│ ╱ Optimal ╲ ╲____
│ ╱ Zone ╲ ╲___
│ ╱ ╲ ╲
│ ╱ ╲ ╲____
│╱ ╲____Death by____╲
│ Efficiency
└───────────────────────────────────────►
Low Waste/Randomness High
(Inverter Activity)
Too little noise: stagnation. Too much: chaos. But in the middle—the “wild zone”—systems thrive.
Her door opens. It’s Greg Engel.
ENGEL
48, tailored shirt, the kind of tan that comes from skiing in Aspen. He discovered quantum coherence in photosynthesis at 30. Nobel buzz since. Now he’s building an empire.
ENGEL: “Ana. You missed the faculty lunch.”
ANA: “Working.”
ENGEL: “On what? That graph is… concerning.”
He sees it. The Inverter Curve. The implication that the Institute’s entire mission—optimizing healthcare through quantum precision—might be dangerous.
ANA: “It’s preliminary.”
ENGEL: “It looks like you’re saying efficiency kills.”
ANA: “I’m saying systems need noise to survive. The same way photosynthetic complexes need vibrational noise to maintain coherence. You taught me that, Greg. Environment-assisted quantum transport.”
ENGEL: “That’s molecular. This is—” he gestures at the whiteboard “—this is an argument against everything we’re building.”
ANA: “Or an argument for building it differently.”
Engel steps closer. Lowers his voice.
ENGEL: “The Board meeting. They’re expecting a presentation on precision risk stratification. Using quantum biomarkers to predict disease before symptoms. Personalized premiums. Optimized outcomes.”
ANA: “And if my model is right, that optimization will kill the innovation that actually cures disease?”
ENGEL: “Your model is economics. Not biology.”
ANA: “My model is information theory. And information theory doesn’t care about departments.”
She pulls up a paper on her screen. Suppressed, buried, but she found it through Sarah’s medical journal access.
ANA: “Dr. Helena Voss. Thames Valley University. Cryptophyte algae with quantum coherence switches. Published 2023. Retracted under pressure from Apex Biologics. Patent dispute.”
Engel stiffens. He knows the name.
ENGEL: “Voss is a crank.”
ANA: “Voss is a geneticist who found biological systems that toggle quantum effects on and off. Evolution selected for quantum control. Do you understand what that means?”
ENGEL: “It means she had bad data.”
ANA: “It means biology measures. It decides when coherence helps and when it hurts. The cryptophytes don’t stay quantum all the time—they switch. Efficiency when light is abundant. Quantum exploration when light is scarce.”
She turns to him, intense.
ANA: “They’re not optimizing, Greg. They’re inverting. When survival requires the least likely path, they take it.”
ENGEL: “And you think healthcare markets should do the same?”
ANA: “I think the ‘waste’ in our system—the redundant research, the failed trials, the competing approaches—that’s not waste. That’s the quantum channel. That’s exploration of low-probability, high-payoff outcomes. If we optimize it away—if we use quantum biomarkers to predict exactly who will respond to exactly which treatment—we eliminate the ‘wild’ that discovers new treatments.”
Engel is quiet. He looks at the tally stick on her desk.
ENGEL: “Your father’s?”
ANA: “He kept inventory for a failing store. Every item marked on wood. When the electronic system crashed—power outage, ransomware, whatever—he had the tally. The low-tech backup. The ‘waste’ of double-entry turned out to be survival.”
ENGEL: “Poetic. But the Board won’t care.”
ANA: “Then maybe I won’t present.”
ENGEL: “Ana.” He softens. “I brought you here because you’re brilliant. Because you see patterns others miss. But you’re also…”
ANA: “Difficult? Disruptive? A liability?”
ENGEL: “Idealistic. This Institute can do real good. Quantum sensing for early cancer detection. Molecular diagnostics. You’re talking about throwing that away because of a theory.”
ANA: “I’m talking about limiting theory. About knowing when to optimize and when to explore. The cryptophytes know. Why don’t we?”
Engel moves to the window. Looks out at the frozen Midway.
ENGEL: “Apex Biologics called me yesterday.”
Ana’s breath catches.
ENGEL: “They know about your interest in Voss. They’re concerned you’re… contaminating the Institute’s reputation with discredited research.”
ANA: “They’re threatened.”
ENGEL: “They’re powerful. And they’re offering partnership. $400 million over ten years. Quantum biomarker platform. Global reach.”
ANA: “If I stop talking about Voss? If I kill the Inverter research?”
ENGEL: “They didn’t say that.”
ANA: “They didn’t have to.”
She stands. Picks up the tally stick. Feels the weight of it.
ANA: “My father didn’t fail because he used wood instead of computers. He failed because the neighborhood changed. Big box stores. Online retail. The economic environment became… optimized. No room for the small, the local, the ‘wasteful.‘”
She looks at Engel.
ANA: “I’m not going to present your precision risk stratification. I’m going to present the Inverter. And if the Board rejects it, I’ll find someone who won’t.”
ENGEL: “There is no one else. Apex owns this space.”
ANA: “Then I’ll build something they don’t own.”
She walks out. Engel doesn’t stop her.
In the hallway, she pulls out her phone. Texts Sarah: “Going to need help. And maybe a lawyer.”
Then she searches for flights to London. Guildford. Thames Valley University.
She needs to find Helena Voss.
ATMOSPHERE NOTES
- The contrast between Ana’s messy humanism and Engel’s polished ambition
- The tally stick as physical symbol—low-tech resilience
- Sarah (off-screen but present) as the human cost
- The Inverter Curve as both scientific model and political threat
THEMES
- Optimization as existential threat
- The value of “waste” and redundancy
- Corporate capture of academic research
- The lineage: Ana seeking Helena, the pattern across time
NEXT SIMULATION TRIGGER
Ana arrives in Guildford. Helena is… where?